Lysosomal Aci​d Lipase Deficiency: Conclusion & Discussion
EAS Academy, Session Speakers, 137180
Triglyceride, Remnants and Atherosclerosis
EAS Academy, Børge Nordestgaard, 136721
Lipid Metabolism Abnormalities in LAL-D as a lysosomal storage disease with a focus on specific signs and symptoms
EAS Academy, Maurizio Averna, 137179
Diabetic Dyslipidaemia
EAS Academy, Alberto Zambon, 136720
Lysosomal Aci​d Lipase Deficiency: Chair
EAS Academy, Petri Kovanen, 137177
Lipid Metabolism Abnormalities in general with differential diagnoses including also LAL-D
EAS Academy, Thomas Stulning, 137178
Low HDL High Triglyceride, Diabetic Dyslipidaemia: Chair
EAS Academy, Olov Wiklund, 137181
NAFLD - THE NOVEL TREAT FOR VASCULAR DISEASE
EAS Academy, Marja-Riitta Taskinen, 136719
TRANSLATING NUTRITIONAL SCIENCE INTO CLINICAL PRACTICE
EAS Academy, Vasanti Malik, 136718
DOES THE HEALTHY METABOLICALLY OBESE PHENOTYPE EXIST?
EAS Academy, Luc Van Gaal, 136717
MANAGEMENT OF SUBJECTS AT HIGH CARDIOMETABOLIC RISK - WHERE DO WE FALL?
EAS Academy, Jean-Pierre Despres, 136716
ADIPOSE TISSUE BROWNING AND METABOLIC HEALTH
EAS Academy, Joerg Heeren, 136713
HOW GENES CONTROL CHOLESTEROL
EAS Academy, Michael S. Brown, 136711
SEX-SPECIFIC GENOMIC AND PROTEOMIC REGULATION IN CARDIOVASCULAR DISEASE
EAS Academy, Georgios Kararigas, 136710
SEX-SPECIFIC BIOMARKERS FOR CARDIOVASCULAR DISEASES
EAS Academy, Børge Nordestgaard, 136709
SEX DIFFERENCES IN HEART DISEASE IN CLINICAL PRACTICE
EAS Academy, Eva Bossano Prescott, 136708
PUBLIC HEALTH PERSPECTIVES ON CARDIOVASCULAR CARE FOR MEN AND WOMEN
EAS Academy, Kornelia Kotseva, 136707
Discussion and Conclusion​
EAS Academy, Session Speakers, 137187
Plant Nutraceuticals for the treatment of hypercholesterolemia: The available clinical data
EAS Academy, Eric Bruckert, 137186
To bridge the gap between lifestyle and Pharmacological treatment: do we have an unmet need?
EAS Academy, bernhard paulweber, 137185
Nutraceuticals with​ lipid lowering activity​: who can benefit?​: Chairman’s welcome
EAS Academy, Gerd Assmann, 137182
Role of Nutrition in Disease Pathology: Discussion
EAS Academy, Session Speakers, 137120
NOVEL INTRANASAL ANTI-CETP VACCINE AGAINST THE DEVELOPMENT OF ATHEROSCLEROSIS AND FATTY LIVER DISEASE
EAS Academy, Jaime Mas-Oliva, 136706
SATURATED FAT IN THE DIET: GOOD OR BAD?
EAS Academy, Ingeborg Brouwer, 136701
CURRENT STATUS-PHASE I TRIAL OF CELL-TRANSPLANTATION THERAPY WITH ALLOGENEIC ADIPOSE TISSUE-DERIVED MULTILINEAGE PROGENITOR CELLS IN SEVERE FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS UNDERGOING LDL-APHERESIS
EAS Academy, Masahiro Koseki, 136705
A NOVEL COMBINATORIAL NON-VIRAL VECTOR TO TREAT FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
EAS Academy, Alastair Kerr, 136704
ROLE OF SODIUM IN ATHEROSCLEROSIS
EAS Academy, Jens M. Titze, 136700
Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians?: Discussion
EAS Academy, Session Speakers, 137119
COMPARATIVE EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION, STATIN AND EZETIMIBE THERAPY ON ATHEROGENIC AND PROTECTIVE LIPID FACTORS: THE ACCENTUATE TRIAL
EAS Academy, Stephen Nicholls, 136703
LESSONS FROM CLINICAL TRIALS
EAS Academy, Jane Armitage, 136699
LESSONS FROM CLINICAL EXPERIENCE
EAS Academy, Urlich Laufs, 136698
ANTI-INFLAMMATORY INTERVENTIONS VERSUS INTENSIVE LDL LOWERING
EAS Academy, Francois Mach, 136702
Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians? Chair
EAS Academy, Chris Packard, 137123
LEADING THE WAY TO GENETICS AND PHARMACOGENOMICS IN THE CLINIC
EAS Academy, Teri Manolio, 136696
GWAS FOR CORONARY ARTERY DISEASE
EAS Academy, Heribert Schunkert, 136695
GENETIC PROTECTION FROM CORONARY ARTERY DISEASE: THE ROLE OF ABCG5 AND ABCG8
EAS Academy, Helen Hobbs, 136694
PANEL DISCUSSION
EAS Academy, Session Speakers, 137188
ROLE OF MICROBIOTA ON CARDIOVASCULAR DISEASE
EAS Academy, Jingyuan Fu, 136680
PLANT STEROL AND STANOLS AND CARDIOVASCULAR DISEASE. IMPACT OF ENRICHED FOODS AND CHOLESTEROL LOWERING DRUGS
EAS Academy, John M. Chapman, 136679
SUGAR INTAKE AND CARDIOVASCULAR DISEASE - SHOULD IT BE THE NEXT FIGHT TO DECREASE CVD?
EAS Academy, Jean-Pierre Despres, 136678
SHOULD SATURATED FAT BE TARGETED FOR THE PREVENTION OF CARDIOVASCULAR DISEASE?
EAS Academy, Alice H. Lichtenstein, 136677
Swedish experience from patient society
EAS Academy, Gunnar Karlsson, 118047
The lipid clinic and organization of FH, the role of different participants in the team
EAS Academy, Kjetil Retterstøl, 118046
FH in children
EAS Academy, Albert Wiegman, 118044
The role of new lipid lowering drugs
EAS Academy, Kausik Ray, 118043
Treatment of FH: Diet, statin and statin intolerance
EAS Academy, Olov Wiklund, 118042
Cascade screening introduction and experience from Czech Republic
EAS Academy, Tomas Freiberger, 118039
Cascade screening introduction and experience from Spain
EAS Academy, Pedro Mata, 118040
Diagnosis of FH: Scoring systems and Genetic diagnosis, Polygenic causes of clinical FH
EAS Academy, Joep Defesche, 118038
Genetics of FH mutation and distribution
EAS Academy, Stefano Romeo, 118037
The population burden of FH- The need to close the gap
EAS Academy, Kausik Ray, 118036
Certificate of Education in Familial Hypercholesterolaemia
EAS Academy, EAS, 113072
Case based approach to Familial Hypercholesterolemia
EAS Academy, EAS, 113071
EAS Training Programme in Lipidology
EAS Academy, EAS, 99063
Personal Information
EAS Academy, EAS, 99259
Personal Information
EAS Academy, EAS, 113067
Module 5: Mendelian randomization approach to understand effect of lipoprotein in causing disease
EAS Academy, Anne Tybjaerg-Hansen, 99034
Investing in your arteries: lifetime management of CVD risk
EAS Academy, John E. Deanfield, 97705
Concluding remarks
EAS Academy, Kausik Ray, 98851
Taking a quantum leap in management strategies
EAS Academy, Seth Baum, 97693
The therapeutic backbone
EAS Academy, Claudia Stefanutti, 97692
Modernising our understanding of HoFH
EAS Academy, Jeanine Roeters van Lennep, 97691
What is the best lipid treatment target? Discussion from the diversity of current guidelines.
EAS Academy, Alberico Luigi Catapano, 97687
What is the role of the different lipoproteins in atherogenesis?
EAS Academy, Jan Borén, 97686
Imaging for estimation risk and disease regression, advancements and new techniques.
EAS Academy, Zahi Fayad, 97685
Future therapies
EAS Academy, Erik Stroes, 97682
Current status of hypolipidaemic therapies
EAS Academy, Chris Packard, 97681
Dyslipidaemias: from lifestyle to genetics
EAS Academy, Kausik Ray, 97680
Engaging with governments- how to get genetic screening into law
EAS Academy, Mario Stoll, 97676
Getting started in your region and Data collation and National governance
EAS Academy, Kausik Ray, 97674
What worked well with the Dutch Database and what we are doing differently for the HoFH database
EAS Academy, Kees Hovingh, 97672
The Ten Countries Study - What's happening in the Asia Pacific Region and synergy with the FHSC
EAS Academy, Gerald Watts, 97671
The potential and limitations of historical data- using UK as an exemplar
EAS Academy, Handrean Soran, 97670
FH Studies Collaboration Symposium and Aims and objectives of the EAS FHSC and the FHSC survey
EAS Academy, Kausik Ray, 97668
EAS Advanced Course Attendance Certificate Upload 1 (mandatory)
EAS Academy, EAS, 98397
EAS Advanced Course or Congress Attendance Certificate Upload 2
EAS Academy, EAS, 98398
What genes can teach about the link between obesity and cardiometabolic traitan integrated approach
EAS Academy, Ruth Loos, 65108
Mendelian randomization: from genetic association to disease mechanism
EAS Academy, Anne Tybjaerg-Hansen, 65107
Genome wide association studies to find genetic determinants of cardiovascular disease
EAS Academy, Olle Melander, 65106
Discussion and data presentation on ANGPTL4
EAS Academy, Stefano Romeo, 65105
Tools to study candidate genes (2)
EAS Academy, Maria Antonella Burza, 65102
ANGPTL3 association and fasting triglycerides
EAS Academy, Stefano Romeo, 65101
Tools to study candidate gene (1)
EAS Academy, Maria Antonella Burza, 65100
Monogenic form of hypercholesterolemia
EAS Academy, Knut Erik Berge, 65097
Module 7: Genetics in cardiovascular disease
EAS Academy, EAS, 65167
Module 11: Pharmacological treatment of other dyslipidemias
EAS Academy, EAS, 65172
EAS Certificate of Excellence in Clinical Lipidology
EAS Academy, EAS, 65181
Consensus papers
EAS Academy, EAS, 113068
Epidemiological and clinical evidence in favour or against clinical utility of different procedures
EAS Academy, Dan O'Leary, 56082
Novel methods
EAS Academy, Erik Stroes, 56083
Classical and Novel Risk Factors
EAS Academy, Naveed Sattar, 56078
PCSK9 INHIBITION
EAS Academy, Bertrand Cariou, 56081
Rebuttal
EAS Academy, Luis Masana Marin, 56099
Rebuttal
EAS Academy, Kausik Ray, 56098
All statins cause diabetes? The case AGAINST the motion
EAS Academy, Luis Masana Marin, 56097
All statins cause diabetes? The case FOR the motion
EAS Academy, Kausik Ray, 56096
From nutrients to food: key features of our diet providing cardio prevention
EAS Academy, Frank Hu, 56073
Lessons from the PREDIMED trial
EAS Academy, Emilio Ros, 56074
Lessons from LOOK AHEAD
EAS Academy, Jean-Pierre Despres, 56075
Physical Activity and CVD risk
EAS Academy, Rainer Rauramaa, 56076

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings